The Kangzhou One Step hCG Test Strip is an in vitro diagnostic visual qualitative immunochromatographic assay designed for the rapid determination of human chorionic gonadotropin (hCG) in urine to aid in the early detection of pregnancy. It is intended for over-the-counter (OTC) use.

The Kangzhou One Step hCG Test Cassette is an in vitro diagnostic visual qualitative immunochromatographic assay designed for the rapid determination of human chorionic gonadotropin (hCG) in urine to aid in the early detection of pregnancy. It is intended for over-the-counter (OTC) use.

The Kangzhou One Step hCG Test Midstream is an in vitro diagnostic visual qualitative immunochromatographic assay designed for the rapid determination of human chorionic gonadotropin (hCG) in urine to aid in the early detection of pregnancy. It is intended for over-the-counter (OTC) use.

Device Description

The Pregnancy One Step Rapid Test is a qualitative, solid phase, two-site sandwich immunoassay for the detection of human chorionic gonadotropin (hCG) in urine, as an aid in the early detection of pregnancy. The membrane is pre-coated with anti-hCG antibodies on the test band region and anti-mouse antibodies on the control band region. During testing, the urine sample reacts with the dye conjugate (mouse anti-hCG antibody-colloidal gold conjugate) which has been pre-coated on the test strip. The mixture then migrates upward on the membrane chromatographically by capillary action to react with anti-hCG antibodies on the membrane and generate a red band. Presence of the red band indicates a positive result, while its absence indicates a negative result. Regardless of the presence of hCG, as the mixture continues to migrate across the membrane to the immobilized goat anti-mouse region, a red band at the control band region will always appear. The presence of this red band serves as verification for sufficient sample volume and proper flow and as a control for the reagents.

AI/ML Overview

The provided FDA 510(k) summary for the Kangzhou One Step hCG Test Strip, Cassette, and Midstream indicates the acceptance criteria and performance of the device.

Here's an analysis of the provided information:

Acceptance Criteria and Reported Device Performance

Acceptance Criteria Category	Acceptance Criteria (Explicitly Stated or Implied by Study Design)	Reported Device Performance
1. Analytical Performance
a. Precision/Reproducibility	Consistent results across multiple runs, days, laboratories, and batches for spiked samples at 0 mIU/mL, 12.5 mIU/mL, 18.75 mIU/mL, 25 mIU/mL, 50 mIU/mL, and 100 mIU/mL.	100% agreement (30/30 for each category, for 3 lots) for negative (0, 12.5, 18.75 mIU/mL) and positive (25, 50, 100 mIU/mL) samples across 3 lots, 3 runs/day for 10 days, in 3 hospital laboratories, for all three formats (strip, cassette, midstream - both dip and simulated midstream methods).
b. Detection Limit/Sensitivity	Detect hCG at 25 mIU/mL.	25 mIU/mL (derived from precision data, where 25 mIU/mL samples consistently showed positive results).
c. Analytical Specificity (Cross-reactivity)	No cross-reactivity with hLH at 500 mIU/mL, hFSH at 1000 mIU/mL, and hTSH at 1000 mIU/mL for both negative and positive (25 mIU/mL hCG) samples.	No cross-reaction observed with hLH at 500 mIU/mL, hFSH at 1000 mIU/mL, and hTSH at 1000 mIU/mL. 100% agreement (60/60 for each hormone and concentration) for negative and positive samples across 3 lots.
d. Analytical Specificity (Interfering Substances)	No interference from specified exogenous compounds and clinical conditions at given concentrations for both negative (0 mIU/mL) and positive (25 mIU/mL hCG) samples.	No interferences observed from a long list of substances (e.g., Acetaminophen, Aspirin, Ascorbic acid, Glucose, Hemoglobin, Albumin, Bilirubin, Leukocyte, Erythrocytes, Uric acid, Ketone, Ethanol) at their specified concentrations.
e. Analytical Specificity (hCG ß-core fragment)	No interference from hCG ß-core fragment at high levels (125,000, 50,000, 500,000 and 1,000,000 pmol/mL) for negative (0 mIU/mL) and positive (25 mIU/mL hCG) samples.	No interference observed in the test result at the highest levels of hCG ß-core fragment.
f. pH Interference	No interference for urine with pH 3-9.	Varying pH ranges (3 to 9 in 1 pH unit increments) do not interfere with the performance of the test for 0 mIU/mL and 25 mIU/mL hCG.
g. Specific Gravity Interference	No interference for urine with specific gravity 1.000-1.040.	No interference observed when specific gravity is between 1.01-1.04 (tested with purified water and 25 mIU/mL hCG).
h. High-Dose Hook Effect	No high-dose hook effect within a specified hCG concentration range.	No high-dose hook effect for hCG up to 1,000,000 mIU/mL. Positive results were obtained over the range of 62,500 to 1,000,000 mIU/mL, though the T-line lightened for concentrations above 125,000 mIU/mL.
2. Professional Method Comparison	High agreement with predicate device when tested by laboratory professionals.	100% agreement with the predicate device (Co-Innovation One Step hCG Test) for all formats (`strip`: 43 positive, 47 negative; `cassette`: 37 positive, 53 negative; `midstream dip`: 55 positive, 35 negative; `midstream simulated`: 50 positive, 40 negative) across two professional laboratories.
3. Lay User Method Comparison	High agreement between lay users and professional laboratory results using the candidate device.	- `Strip`: 100% (43 Positive, 47 Negative).- `Cassette`: 100% (37 Positive, 53 Negative).- `Midstream (dip method)`: 100% (55 Positive, 35 Negative).- `Midstream (actual midstream method)`: 100% (50 Positive, 40 Negative).
4. Performance Tested by OTC User	Lay users, including untrained operators, should obtain correct results comparable to professional users, and find the test easy to read and interpret.	100% agreement (30/30 for positive 31.25 mIU/mL and 30/30 for negative 18.75 mIU/mL) for all formats tested by lay users compared to masked spiked samples tested by professional users. All participants found the test "very easy" or "easy" to read and interpret.
5. Clinical Cut-off	25 mIU/mL	25 mIU/mL

Study Details

Sample Size used for the test set and the data provenance:
- Precision/Reproducibility: 30 clinical samples (urine) from normal, non-pregnant females, spiked with hCG at different concentrations (0, 12.75, 25, 25, 100 mIU/mL - note the repeated 25 mIU/mL in the text, likely a typo for an additional concentration or indication of testing at the cut-off).
- Analytical Specificity (Cross-reactivity): 60 fresh urine specimens from healthy non-pregnant females.
- Analytical Specificity (Interfering Substances): Normal, non-pregnant female urine specimens (number not specified but implied to be sufficient for testing various substances in both 0 and 25 mIU/mL hCG spiked samples).
- Analytical Specificity (hCG ß-core fragment): Normal non-pregnant female urine specimens (number not specified but implied to be sufficient for testing different fragment concentrations in both 0 and 25 mIU/mL hCG spiked samples).
- pH & Specific Gravity Interference: Aliquots of a negative urine pool and specimens with 25 mIU/mL hCG.
- High-Dose Hook Effect: HCG-free specimens spiked with hCG at various high concentrations.
- Professional Method Comparison: Urine samples from 360 women (patients suspected of pregnancy, late periods, or later in pregnancy).
- Lay User Method Comparison: Urine samples from 360 women (same as professional comparison, but tested by lay users).
- Performance Tested by OTC User: 240 aliquots of spiked urine samples (120 at 18.75 mIU/mL and 120 at 31.25 mIU/mL hCG). 240 female subjects participated.
- Data Provenance:
  - Precision/Reproducibility: Clinical samples from China (implied by manufacturer location). Data collected from 3 hospital laboratories.
  - Professional Method Comparison: Urine samples collected from hospitals (implied by "women at hospital laboratory") in China (implied by manufacturer location).
  - Lay User Method Comparison: Urine samples collected from hospitals (implied by "women at hospital laboratory") in China.
  - Performance Tested by OTC User: The study was performed at 3 different point-of-care sites in Shanghai, Qingdao, and Beijing, China.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Precision/Reproducibility: The spiked samples' concentrations were determined by immunoassay of ELISA, implying a laboratory setting and likely qualified personnel, but the specific number or qualifications of "experts" for ground truth are not stated.
- Professional Method Comparison: Ground truth was established by comparing the candidate device to a legally marketed predicate device (K132085, Co-Innovation One Step hCG Test Strip/Cassette/Midstream), tested by "laboratory professionals" (number and specific qualifications not mentioned).
- Lay User Method Comparison: Ground truth for professional comparison was the predicate device. For the comparison of lay user results to candidate device professional results, the ground truth was the professional interpretation of the candidate device. "Laboratory professionals" are mentioned, but their number and specific qualifications are not.
- Performance Tested by OTC User: Ground truth was established by "professional laboratory personnel at the manufacturer site" testing "masked spiked urine." The number and specific qualifications of these personnel are not stated.
Adjudication method (e.g., 2+1, 3+1, none) for the test set:
- The document does not explicitly describe an adjudication method with multiple readers for discrepancy resolution (like 2+1 or 3+1). For the professional method comparison and lay user comparison, agreement was measured against a reference method (predicate device or professional readings of the candidate device). For spiked samples, the known concentration (via ELISA) served as the objective reference.
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This device is a rapid diagnostic test (HCG pregnancy test) and AI assistance is not part of its design. The studies performed were for device performance and usability by professionals and lay users.
If a standalone (i.e. algorithm only without human-in-the loop performance) was done:
- No, this is a visual qualitative immunochromatographic assay, not an algorithm-only device. Its performance is human-in-the-loop, as the results are visually interpreted. The "standalone" performance closest to this concept is the analytical performance studies (precision, sensitivity, specificity) which characterize the inherent chemical and biological function of the test strip/cassette/midstream.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- Analytical Performance (Precision, Sensitivity, Specificity, Interference, etc.): Known concentrations of spiked hCG and interfering substances, determined by immunoassay (ELISA) or reference standards (e.g., WHO IS for hCG and hormones). This is a form of analytical reference method or objective known values.
- Professional Method Comparison: Comparison against a legally marketed predicate device.
- Lay User Method Comparison: Comparison against professional readings of the candidate device (which itself was compared to a predicate) or professional readings of masked spiked samples with known concentrations.
The sample size for the training set:
- This document describes performance evaluation studies for a rapid diagnostic test, not a machine learning model. Therefore, there is no "training set" in the context of AI/ML. The device's design is based on chemical and biological principles.
How the ground truth for the training set was established:
- As there is no training set for an AI/ML model, this question is not applicable.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left, there is a symbol representing the Department of Health & Human Services - USA. To the right of the symbol, the FDA logo is displayed in blue, with the words "U.S. FOOD & DRUG" stacked above the word "ADMINISTRATION".

January 10, 2019

Weihai Kangzhou Biotechnology Engineering Co., Ltd % Ravmond Luo. Technical Manager Shanghai SUNGO Management Consulting Company Limited 1500# Century Avenue, Room 1309 Shanghai, 200122 China

Re: K183097

Trade/Device Name: Kangzhou One Step hCG Test Strip Kangzhou One Step hCG Test Cassette Kangzhou One Step hCG Test Midstream Regulation Number: 21 CFR 862.1155 Regulation Name: Human chorionic gonadotropin (HCG) test system Regulatory Class: Class II Product Code: LCX Dated: November 5, 2018 Received: November 13, 2018

Dear Raymond Luo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or post marketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Kellie B. Kelm -S

for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K183097

Device Name

Kangzhou One Step hCG Test Strip Kangzhou One Step hCG Test Cassette Kangzhou One Step hCG Test Midstream

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
-------------------------------------------------	--

Prescription Use (Part 21 CFR 801 Subpart D)

|X | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

Section 5:

510(K) Summary

K183097

Date of Summary Preparation: January 3rd, 2019

A. Applicant

Name: Weihai Kangzhou Biotechnology Engineering Co., Ltd Address: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City, Shandong, People's Republic of China

Official Contact Person Information Name: Raymond Luo Tel: 0086-21-68828050 Mail: fda.sungo@gmail.com

B. Device

Kangzhou One Step hCG Test Strip Trade name: Kangzhou One Step hCG Test Cassette Kangzhou One Step hCG Test Midstream Common name: KIT, TEST, PREGNANCY, HCG, OVER THE COUNTER KIT, TEST, PREGNANCY, HCG, OVER THE COUNTER Classification name: Regulation Medical Specialty Clinical Chemistry Regulation Number 862.1155 LCX Product Code Classification Class II

C. Predicate device

510 (K) Number: K132085 Co-Innovation One Step hCG Test Strip Co-Innovation One Step hCG Test Cassette Co-Innovation One Step hCG Test Midstream Produced by Co-Innovation Biotech Company Ltd.

D. Intended use of the device

Intended use(s):

The Kangzhou One Step hCG Test Strip is an in vitro diagnostic visual qualitative

{4}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

immunochromatographic assay designed for the rapid determination of human chorionic gonadotropin (hCG) in urine to aid in the early detection of pregnancy. It is intended for over-the-counter (OTC) use.

E. Device Description

{5}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

Image /page/5/Figure/3 description: The image shows three different types of pregnancy tests. The first test is a midstream test, which is a plastic device that is held in the urine stream. The second test is a test strip, which is a paper strip that is dipped in urine. The third test is a test cassette, which is a plastic device that has a small window where the test result is displayed. The image also includes a supporter interpretation card.

F. Comparison with predicate

A summary comparison of features of the Kangzhou One Step hCG Test and the predicate devices is provided in the following Table:

Device	New Device	Predicate Device (K132085)
Manufacturer	Weihai KangzhouBiotechnologyEngineering Co., Ltd	Co-Innovation BiotechCompany Ltd.
Intended use	Qualitative detection ofhuman chorionicgonadotropin ("HCG") inurine	Same
Specimen	Urine	Same
Clinical cut-off	25mIU/mL	Same
Indications	Over the Counter (OTC)	Same
Read time	5 minutes	Same

{6}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Test Principle	Colloidal GoldImmunoassay	Same
Traceability	WHO 5th IS	WHO 3rd IS
Format	Strip, cassette, midstream	Same
Result	Qualitative	Same
Antibodies	Monoclonal anti-β hCGantibody colloidal goldconjugate on the pre-driedpad. Monoclonal anti-αhCG antibodies (on thetest region) Goat antimouse IgG (on the controlregion).	Same
Sensitivity	25mIU/mL	Same
Specificity	LH at 500mIU/mL, FSH at1000 mIU/mL, and TSH at1000 mIU/mL	Same
pH Interference	No interference for urinewith pH 3-9	Same
Specific GravityInterference	No interference for urinewith Specific Gravity1.000-1.040	Same
High DosageHook effect	No high dosage hookeffect for hCG up to1.000.000 mIU/mL	Same

Shandong, People's Republic of China

There are no differences identified between new device and the predicate device for intended use, clinical cut-off, read time, test principle, test format, etc. The only difference identified is that the assay of the new device is traceable to the WHO 5* International Standard reference material, while the assay of the predicate device is traceable to the WHO 3d International Standard reference material. However, this difference does not have any significant impact on the safety or performance of the device. The Kangzhou One Step hCG Test Strip/cassette/midstream, and the predicate device, Co-Innovation One Step hCG Test Strip/cassette/midstream (K132085) use the same chemistry with essentially the same test design, thus they are substantial equivalent.

G. Standard/Guidance Document Referenced (if applicable)

Guidance for Over-the Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s

H. Test Principle

The assay of each device uses a double antibody sandwich method. Each test device contains mouse monoclonal anti-ß-hCG antibody colloidal gold conjugate pre-dried on a pad. Mouse

{7}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

monoclonal anti-α-hCG antibody (on the Test Line) and goat anti mouse IgG polyclonal antibody (on the Control Line) are coated and immobilized on a nitrocellulose membrane. During the test procedures, hCG in the urine specimen reacts with the dye conjugate (mouse anti-β-hCG antibody-colloidal gold conjugate specific to the beta subunit of hCG) and forms a complex. Because of capillary and chromatographic effects of the nitrocellulose membrane, the complex migrates along the membrane to the a-hCG antibody line (T), and remains captured in the T line. As a result a red colored band develops in the T line, indicating a positive result. If there is no hCG in the urine, there is no red band in the test zone, indicating a negative result. The Control line should develop in the control zone regardless of the test result.

l. Antibody Information

Antibody	The biological source	The location	Specific antigen
Monoclonalanti-p-HCG antibody	Mouse	Conjugate pad	Specific to the betasubunit of hCG
Monoclonalanti-a-H-CG antibody	Mouse	Nitrocellulosemembrane	Specific to the alphasubunit of hCG
goat anti mouse IgGpolyclonal antibody	Goat	Nitrocellulosemembrane

J. Components and Function of Internal Control

The membrane is pre-coated with anti-mouse antibodies on the control band region. During the testing, the mixture continues to migrate across the membrane to the immobilized goat anti-mouse region, a red band at the control band region will always appear. The presence of this red band serves as verification for sufficient sample volume and proper flow and as a control for the reagents. The Control line should develop in the control zone regardless of the test result. A red line appearing in the control region ( background in the results window in considered an internal negative procedural control. If the Control (C) line does not give the expected reaction on any sample, the test is invalid, and must be repeated.

K. Performance characteristic

1. Analytical performance

a. Precision/Reproducibility:

30 clinical samples were took from normal, nonpregnant females spiked with the HCG (traceable to WHO 5th IS ) at different concentration 0mlU/ml, 12.75mlU/ml, 25mlU/ml, 25mlU/ml, 100mIU/ml (all the concentration was determined by immunoassay of ELISA). The controls were build coded. Separate sets of the blind coded were assigned. Samples were also randomized prior to testing. The study was conducted 3 runs / day and lasted 10 days and was conducted by 3 hospital laboratories. There are 3 batches Kangzhou One Step HCG Test of three formats and each laboratory should conduct one batch separately. The midstream format were performed with both of these midstream test sample application methods (simulated midstream and dip). the result was recorded as the following:

{8}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

The results of precision (strip)

HCG	LOT 1		LOT 2		LOT 3
concentration	positive	negative	positive	negative	positive	negative
0mIU/ml	0	30	0	30	0	30
12.5mIU/ml	0	30	0	30	0	30
18.75mIU/ml	0	30	0	30	0	30
25mIU/ml	30	0	30	0	30	0
50mIU/ml	30	0	30	0	30	0
100mIU/ml	30	0	30	0	30	0

The results of precision (cassette)

HCG	LOT 1		LOT 2		LOT 3
concentration	positive	negative	positive	negative	positive	negative
0mIU/ml	0	30	0	30	0	30
12.5mIU/ml	0	30	0	30	0	30
18.75mIU/ml	0	30	0	30	0	30
25mIU/ml	30	0	30	0	30	0
50mIU/ml	30	0	30	0	30	0
100mIU/ml	30	0	30	0	30	0

The results of precision (midstream, using the dip method)

HCG	LOT 1		LOT 2		LOT 3
concentration	positive	negative	positive	negative	positive	negative
0mIU/ml	0	30	0	30	0	30
12.5mIU/ml	0	30	0	30	0	30
18.75mIU/ml	0	30	0	30	0	30
25mIU/ml	30	0	30	0	30	0
50mIU/ml	30	0	30	0	30	0
100mIU/ml	30	0	30	0	30	0

The results of precision (midstream, using the simulated midstream method)

HCGconcentration	LOT 1		LOT 2		LOT 3
	positive	negative	positive	negative	positive	negative
0mlU/ml	0	30	0	30	0	30
12.5mlU/ml	0	30	0	30	0	30
18.75mlU/ml	0	30	0	30	0	30

{9}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

25mIU/ml	30	0	30	0	30	0
50mIU/ml	30	0	30	0	30	0
100mIU/ml	30	0	30	0	30	0

Shandong, People's Republic of China

The results show that the precision of Kangzhou One Step HCG Test in 3 batches of different formats are good. Kangzhou One Step HCG Test exhibited reproducibility of results.

b. Linearity/assay reportable range:

Not applicable. This is a qualitative assay.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability:

The 510(k) describes traceability of the assay to the WHO 5th reference material. Stability testing information (protocols and acceptance criteria) to support the claimed shelf life (2 years) was reviewed and deemed acceptable.

Stability:

The stability data supports that the products have the shelf life of 36 months when stored at

2-30 ℃.

d. Detection limit/Sensitivity study:

See Precision section above. According to the results of precision data above, the sensitivity of Kangzhou One Step HCG Test is 25mlU/ml.

e. Analytical specificity:

e.1) To evaluate cross-reactivity, 60 fresh urine specimens obtained from healthy non- pregnant females were spiked with different concentrations of Lutenizing Hormone (LH), Follicle stimulating Hormone (FSH), and thyroid stimulating hormone (TSH) into negative (0 mIU/mL) and positive (25mlU/ml) samples. 3 lots of samples were tested. The results demonstrated no cross reaction with LH at 500mIU/ml, FSH at 1000 mlU/mL, and TSH at 1000 mIU/mL. Results are tabulated below.

Results of the negative sample

	Lot 1		Lot 2		Lot 3
	Positive	Negative	Positive	Negative	Positive	Negative
500 mIU/mL hLH	0	60	0	60	0	60
1000 mIU/mL hFSH	0	60	0	60	0	60
1000 mIU/mL hTSH	0	60	0	60	0	60

Results of the positive sample

ﻟﻠﻘﻀﺎﺀ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﮯ۔ ﯾﺎ ﮐﺎ ﮐﺎ ﮐﺎ ﮨﺎﺋﺸﯽ ﮐﮯ ﺳﺎﺗﮫ ﺍﻭﺭ ﺍﺱ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮐﮯ ﺳﺎﺗﮫ ﺍﻭﺭ ﺍﺱ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮐﮯ ﺳﺎﺗﮫ ﺍﻭﺭ ﺍﺱ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎ

{10}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

	Positive	Positive	Positive
500 mIU/mL hLH	60	60	60
1000 mIU/mL hFSH	60	60	60
1000 mIU/mL hTSH	60	60	60

Shandong, People's Republic of China

The standards used in this evaluation were: hLH, WHO 2nd IS (80/552); hFSH, WHO 2nd IRP (78/549); hTSH, WHO 2nd IRP (80/558).

e.2) To evaluate the potential for interference by certain exogenous compounds and potentially interfering clinical conditions. Each substance was prepared by diluting stock interference material to the desired concentration. Normal, nonpregnant female's urine specimens containing 0 and 25mlU/ml HCG were spiked with the interferents to obtain the desired test concentration. Three batches of each format were tested. The results show that no interferences were observed from substance at the following concentrations for both negative and positive HCG urine samples.

Interfering substances	Substances concentration
Acetaminophen	20mg/dL
Aspirin	20mg/dL
Ascorbic acid	20mg/dL
Atropine	20mg/dL
Caffeine	20mg/dL
Glucose	2000mg/dL
Hemoglobin	500mg/dL
Tetracycline	20mg/dL
Ampicillin	20mg/dL
Albumin	2000mg/dL
Bilirubin	2mg/dL
Leukocyte	> 500/ul
Erythrocytes	> 250/uL
Uric acid	0.58 mMol/L
Ketone	> 80 mg/dL
Ethanol	1%

e.3) To evaluate the effects of the HCG ß-core fragment normal nonpregnant female urine specimens containing 0 and 25mlU/ml HCG were spiked with the HCG ß-core fragment (traceable to WHO reference reagent 99/708) at the concentration of 125000, 50000, 500000 and 1000000 pmol/mL. Three batches of each format were tested. The data shows that there's no interference in the test result when the HCG ß-core fragment at the highest levels at which it is likely to be found on patient samples.

e.4) PH study

The PH of an aliquot negative urine pool is adjusted to a PH range of 3 to 9 in 1 PH unit increments

{11}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

and spiked with HCG at 25mlU/ml and 0mlU/ml and 3 batches of Kangzhou One Step HCG Test were tested repeatedly. The result demonstrates that varying ranged of PH do not interfere with the performance of the test.

e.5) Specific gravity

Purified water and specimen with HCG 25mIU/ml were formulated into the solution with specific gravity at 1.01, 1.02, 1.03, 1.04 separately. Three lots of Kangzhou One Step HCG Test were tested. The data show that there's no interference in the test result when the specific gravity is between 1.01-1.04.

e.6) HOOK effect study

The test was evaluated for high dose hook effect. HCG free specimens spiked with the HCG at different concentration containing 62500mlU/ml, 25000mlU/ml, 25000mlU/ml, 500000mlU/ml, 1000000mlU/ml. Three lot of tests were tested. The result show that Kangzhou One Step HCG Test can get the positive result when the HCG concentration is range from 62,500 to 1,000,000mlU/ml, while the T line get to light as the concentration above 125,000mIU/ml.

2. Comparison studies:

a. Professional method comparison

Urine samples were collected from 360 women at hospital laboratory to test for pregnancy. Patients included women who suspected pregnancy, and who had late periods, as well as those later in pregnancy. Samples were randomly collected at various times throughout the day. Ages were from 18 to 45 years. Each specimen was blind coded. Separate sets of the blind coded were assigned. Samples were also randomized prior to testing. The tests performed by laboratory professionals were conducted at two laboratories (namely professional A and professional B). Each person tested the candidate device and the predicate device at the same time, but not sequentially. The data show that the agreement of Kangzhou One Step HCG Test with the predicate device was 100%.

Candidate device		Predicate device professional
		Positive	Negative
Professional A	Positive	43	0
	Negative	0	47
Professional B	Positive	43	0
	Negative	0	47

The results of professional method comparison (strip)

The results of professional method comparison (cassette)

Candidate device	Predicate device professional
------------------	-------------------------------

{12}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

		Positive	Negative
Professional A	Positive	37	0
	Negative	0	53
Professional B	Positive	37	0
	Negative	0	53

Shandong, People's Republic of China

The results of professional method comparison (midstream, using dip method)

Candidate device		Predicate device professional
		Positive	Negative
Professional A	Positive	ર્દે ર	O
	Negative	0	રે રેણવાડી તેમ જ દૂધની ડેરી જેવી સવલતો પ્રાપ્ય થયેલી છે. આ ગામનાં લોકોનો મુખ્ય વ્યવસાય ખેતી, ખેતમજૂરી તેમ જ પશુપાલન છે. આ ગામમાં મુખ્યત્વે ખેત-ઉપય
Professional B	Positive	ટેટ	O
	Negative	O	35

The results of professional method comparison (midstream, using the simulated method)

Candidate device		Predicate device professional
		Positive	Negative
Professional A	Positive	50	0
	Negative	0	40
Professional B	Positive	50	0
	Negative	0	40

b. The lay user method comparison:

Urine samples were collected from 360 women at hospital laboratory to test for pregnancy. Ages were from 18 to 45 years. The 360 lay users test their own urine using the English package insert as guide to perform the test. This included 90 lay users using test strip, 90 using test cassette, 180 using actual midstream method and the dip method respectively for test midstream. They were asked to fill out and English questionnaire after finishing the test and collected samples for tests by laboratory professionals using the candidate devices. Each specimen was blind coded. Separate sets of the blind coded were assigned. Samples were also randomized prior to tests performed by laboratory professionals were conducted at a laboratory.

The results of the lay user method comparison (strip)

Candidate device	Candidate device professional
	Positive	Negative
Lay users	Positive	43	0

{13}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

Negative	0	47
----------	---	----

The results of the lay user method comparison (cassette)

Candidate device		Candidate device professional
		Positive	Negative
Lay users	Positive	37	0
	Negative	0	53

The results of the lay user method comparison (midstream, using dip method)

Candidate device	Candidate device professional
	Positive	Negative
Lay users	Positive	55	0
	Negative	0	35

The results of the lay user method comparison (midstream, using the actual midstream method)

	Candidate device	Candidate device professional
		Positive	Negative
Layusers	Positive	50	0
	Negative	0	40

c. The performance tested by OTC user:

To evaluate its suitability to be used by the home use consumers (lay persons), spiked urine samples were tested by the lay persons and the results were compared with professional laboratory results. The study was performed at 3 different point-of-care sites in Shanghai, Qingdao and Beijing. HCG free specimens spiked with the HCG (material traceable to WHO 5th IS) at 18.75mlU/ml and 31.25mlU/ml. Both the concentration was determined by immunoassay of ELISA. Each concentration urine specimens were divided into 120 individual containers for a total of 240 aliquot. All aliquot were blindly labeled by a nonparticipant. Samples were also randomized prior to testing. 240 female subjected with various education backgrounds and the ages from 18 to 45 participated in the lay user study. All of the subjects had no the experience of using the test before and were the untrained operators. Each subject conducted 1 test on one test format or one sample application method for the "midstream" using the English package insert as guide. Masked spiked urine were tested by professional laboratory personnel at the manufacturer site. The results show that Kangzhou One Step HCG Test can be used by the untrained operator and get the correct results.

{14}------------------------------------------------

Add: Room401, Building B, Innovation Entrepreneurship Base, High District, Weihai City,

Shandong, People's Republic of China

Results of performance tested by OTC user

Formats	Masked spiked sample	Masked spiked sample	Masked spiked sample Professional users
	Lay users	+(31.25mIU/ml)	+(31.25mIU/ml)	-(18.75mIU/ml)
strip	Lay users	+(31.25mIU/ml)	30	0
	Lay users	-(18.75mIU/ml)	0	30
Cassette	Lay users	+(31.25mIU/ml)	30	0
	Lay users	-(18.75mIU/ml)	0	30
Midstream, using dipmethod	Lay users	+(31.25mIU/ml)	30	0
	Lay users	-(18.75mIU/ml)	0	30
Midstream, using thesimulated midstreammethod	Lay users	+(31.25mIU/ml)	30	0
	Lay users	-(18.75mIU/ml)	0	30

After recording their results, participants were asked to evaluate the test. All participants thought the test was either "very easy" or "easy" to read and interpret (on a scale ranging from very difficult to very easy).

d. Matrix comparison: Not applicable.

Clinical studies: a. Clinical Sensitivity: Not applicable. b. Clinical specificity: Not applicable. c. Other clinical supportive data (when a. and b. are not applicable): 4. Clinical cut-off: 2SmIU/mL 5. Expected values/Reference range: Not applicable

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

Regulation Number and Section

§ 862.1155 Human chorionic gonadotropin (HCG) test system.

(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.